Opioid Overdose Treatment Market (2024 - 2034)
Opioid Overdose Treatment Market Study by Opioid Antagonists, Partial Agonists, Full Agonists, Combination Drugs, and Supportive Medications for Prescription and OTC Sales from 2024 to 2034
Core Findings
FREE CustomizationOpioid Overdose Treatment Market Outlook (2024 to 2034)
The global opioid overdose treatment market is valued at US$ 1.54 billion in 2024, as revealed in a newly published report by Fact.MR. Over the assessment period (2024 to 2034), the market is forecasted to advance at a CAGR of 7.2% and reach a US$ 3.1 billion by the end of 2034.
Overdose of opioids can be fatal because of its adverse effects on the brain, which works for regulating breathing. Difficulties in breathing, unconsciousness, and pinpoint pupils are some of the symptoms witnessed during an opioid overdose. Growing incidence of opioid overdose around the world is attributed to its excessive consumption to manage chronic pain.
Geriatric people, males, and individuals with comparatively low socio-economic conditions are comparatively at a higher risk of opioid overdose compared to the female population, people of high socio-economic condition, and people of young age. Timely administration of drugs and basic life support help in the reversal of opioid overdose, which is driving market players to come up with more effective treatment solutions.
- Worldwide demand for opioid antagonists is evaluated to increase at a CAGR of 7.8% and reach a market value of US$ 1.06 billion by 2034-end.
- Global sales of naloxone are analyzed to rise at 8.6% CAGR and reach US$ 1.11 billion by 2034.
- Prescription (Rx)-based sales of opioid overdose treatment solutions are approximated to accelerate at a CAGR of 7.2% and reach US$ 2.71 billion by the end of 2034.
- The market in South Korea is projected to advance at 7.8% CAGR from 2024 to 2034.
- Demand for opioid overdose treatment in Canada is projected to accelerate at a CAGR of 9.8% through 2034.
| Report Attribute | Detail |
|---|---|
| Opioid Overdose Treatment Market Size (2024E) | US$ 1.54 Billion |
| Forecasted Market Value (2034F) | US$ 3.1 Billion |
| Global Market Growth Rate (2024 to 2034) | 7.2% CAGR |
| Market Share of Rehabilitation Centers (2034F) | 29.7% |
| North America Market Share (2034F) | 43.9% |
| India Market Growth Rate (2024 to 2034) | 11.2% CAGR |
| Key Companies Profiled | Amneal Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Biotoscana; Collegium Pharmaceutical; EMS Pharma; Endo International; Ethypharm; Eurofarma; GlaxoSmithKline; Hikma Pharmaceuticals; Johnson & Johnson; Mallinckrodt Pharmaceuticals; Mundipharma; Mylan; Novartis; Pfizer; Purdue Pharma; Sanofi; Stada Arzneimittel; Takeda; Teva Pharmaceuticals. |
Why is the Opioid Overdose Treatment Market Size Expanding at a Brisk Pace?
“Adverse Impacts of Opioid Overdose Leading to Life-Threatening Incidents”
An opioid overdose, in combination with several other substances, such as sedatives, alcohol, or stimulants, occurs when opioids adversely affect part of the human brain that regulates breathing. Unconsciousness or unresponsiveness, shallowness, stopped or slowed breathing, pinpoint pupils, cold or clammy skin, gurgling or snoring sounds from the mouth, and blue lips are some of the symptoms of an opioid overdose. These issues lead to ineffective breathing issues, and in severe cases, even death. A person experiencing an opioid overdose requires naloxone and immediate healthcare to prevent critical health issues.
What is a Critical Issue Faced in This Market Space?
“Limited Options Available for Treatment of Opioid Overdose”
Naloxone is currently used as one of the more effective treatment options against an overdose of opioids. It is used for the reversal of adverse effects of opioids, such as respiratory depression. However, there aren’t many other treatment options, and this limitation has been adversely impacting opioid treatment market growth opportunities.
What is Assisting Startups Increase Their Market Share?
“Investing in R&D Activities to Explore New Treatment Options”
A key opioid overdose treatment market trend is that new companies are investing heavily in R&D activities for the exploration of new treatment options against opioid overdose. This will help them attract a larger base of end users, such as healthcare professionals, to tackle crucial medical situations.
Country-wise Insights
As per this newly published research report by Fact.MR, a market research and competitive intelligence provider, North America is projected to hold 43.9% of the global opioid overdose treatment market share by the end of 2034. High demand for opioid overdose treatment solutions in the region is owing to rising cases of chronic pain and mental health disorders, which is driving the consumption of opioids. People aged around 18 to 45 years are the predominating group experiencing chronic issues, which is generating remunerative opportunities for providers of opioid overdose treatment options.
Why is the United States a Key Market for Opioid Overdose Treatment?
“High Number of Cases of Opioid Overdose in the Country”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 577.1 Million |
| Growth Rate (2024 to 2034) | 7.8% CAGR |
| Projected Value (2034F) | US$ 1.22 Billion |
The United States is forecasted to occupy a market share of 85% in North America by the end of 2034.
- A report ‘Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths – United States, 2023 to 2019’ was published by Morbidity and Mortality Weekly Report, on February 12, 2021. This report stated that 70,630 people died in the United States of America in 2019 due to drug overdose and approx. half of these deaths involved synthetic opioids.
Such increasing incidents of opioid overdose are resulting in the high requirement for effective treatment solutions to save lives and combat the overdose menace.
What’s Helping Opioid Overdose Treatment Solution Providers in Japan?
“Implementation of Supportive Government Policies”
| Attribute | Japan |
|---|---|
| Market Value (2024E) | US$ 70.5 Million |
| Growth Rate (2024 to 2034) | 2.8% CAGR |
| Projected Value (2034F) | US$ 93.2 Million |
Japan is evaluated to hold 20.3% share of the East Asian market revenue by the end of 2034. The government in Japan takes healthcare seriously and has laid down several regulations concerning opioid medications. This is driving the development of medications required for treating opioid overdose in the country.
Category-wise Insights
Global demand for prescription-based opioid overdose treatment solutions is forecasted to increase at a CAGR of 7.2% and reach a market valuation of US$ 2.71 billion by the end of 2034. Growing prominence for these modes of sales is attributed to the safety, trust, and authenticity associated with the medications offered.
Which Drug Class is Popular for Opioid Overdose Treatment?
“Assistance of Antagonists in Effectively Blocking Effects of Opioids”
| Attribute | Opioid Antagonists |
|---|---|
| Segment Value (2024E) | US$ 502.2 Million |
| Growth Rate (2024 to 2034) | 7.8% CAGR |
| Projected Value (2034F) | US$ 1.06 Billion |
The opioid antagonist drug class is projected to account for 34.3% share of the global market by 2034. These drugs are used to block the effects of some common opioids, where naltrexone is highly popular. They help in the treatment of opioid overdose. In addition, their assistance in treating opioid use disorders, opioid-induced constipation, and alcohol disorders is contributing to increased demand among healthcare providers around the world.
Which Opioid Overdose Treatment Drugs Have Gained Prominence?
“Increasing Consumption of Naloxone for Effectively Destroying Opioids”
| Attribute | Naloxone |
|---|---|
| Market Value (2024E) | US$ 489.5 Million |
| Growth Rate (2024 to 2034) | 8.6% CAGR |
| Projected Value (2034F) | US$ 1.11 Billion |
Naloxone is approximated to contribute 36% share of global market revenue by the end of 2034. This is an FDA (Food & Drug Administration)-approved antidote that is used for the reversal and blocking effects caused due to the overdose of opioids such as oxycodone, morphine, and heroin. Growing demand for naloxone is attributed to its ability to find opioids and then rip them off and block the same.
Which End User Accounts for High Revenue Generation?
“High Demand for Opioid Overdose Treatment Solutions in Rehabilitation Centers”
| Attribute | Rehabilitation Centers |
|---|---|
| Segment Value (2024E) | US$ 460.1 Million |
| Growth Rate (2024 to 2034) | 7.2% CAGR |
| Projected Value (2034F) | US$ 920.5 Million |
Rehabilitation centers are analyzed to account for a share of 29.7% of the global market by 2034. High demand for opioid overdose treatment solutions in rehabilitation centers for opioid overdose, such as buprenorphine or methadone, is creating remunerative opportunities for market players globally. They are utilized at these centers for opioid agonist withdrawal management and maintenance therapy.
Competitive Landscape
Key players in the opioid overdose treatment industry are looking to develop more advanced and effective treatment solutions to ensure efficiency in outcomes.
For instance:
- Naloxone HCI Nasal Spray of Amneal got approval from the United States FDA in April 2024. This is a widely used spray that helps in the treatment of opioid drug overdose.
Fact.MR provides detailed information about the price points of key players in the opioid overdose treatment market positioned across the world, sales growth, production capacity, and speculative technological expansion, in this newly published market report.
Segmentation of Opioid Overdose Treatment Market Research
-
By Drug Class :
- Opioid Antagonists
- Partial Agonists
- Full Agonists
- Combination Drugs
- Supportive Medications
- Others
-
By Drug :
- Naloxone
- Buprenorphine
- Methadone
- Naltrexone
- Lofexidine
- Extended-release Buprenorphine
- Extended-release Naltrexone
- Buprenorphine Implant
- Buprenorphine Buccal Film
- Other Drugs
-
By Mode of Sale :
- Prescription (Rx)
- Over-the-Counter (OTC)
-
By End User :
- Hospitals
- Emergency Departments
- Rehabilitation Centers
- Outpatient Clinics
- Community Health Centers
- Others
-
By Region :
- North America
- Latin America
- Western Europe
- Eastern Europe
- East Asia
- South Asia & Pacific
- MEA
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 6.1. Drug Class
- 6.2. Drug
- 6.3. Mode of Sale
- 6.4. End User
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
- 7.1. Opioid Antagonists
- 7.2. Partial Agonists
- 7.3. Full Agonists
- 7.4. Combination Drugs
- 7.5. Supportive Medications
- 7.6. Others
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug
- 8.1. Naloxone
- 8.2. Buprenorphine
- 8.3. Methadone
- 8.4. Naltrexone
- 8.5. Lofexidine
- 8.6. Extended-release Buprenorphine
- 8.7. Extended-release Naltrexone
- 8.8. Buprenorphine Implant
- 8.9. Buprenorphine Buccal Film
- 8.10. Other Drugs
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Mode of Sale
- 9.1. Prescription (Rx)
- 9.2. Over-the-Counter (OTC)
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by End User
- 10.1. Hospitals
- 10.2. Emergency Departments
- 10.3. Rehabilitation Centers
- 10.4. Outpatient Clinics
- 10.5. Community Health Centers
- 10.6. Others
- 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Western Europe
- 11.4. Eastern Europe
- 11.5. East Asia
- 11.6. South Asia & Pacific
- 11.7. Middle East & Africa
- 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 19. Sales Forecast 2024 to 2034 by Drug Class, Drug, Mode of Sale, End User, and Region for 30 Countries
- 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 21. Company Profile
- 21.1. Amneal Pharmaceuticals
- 21.2. Astellas Pharma
- 21.3. AstraZeneca
- 21.4. Bayer
- 21.5. Biotoscana
- 21.6. Collegium Pharmaceutical
- 21.7. EMS Pharma
- 21.8. Endo International
- 21.9. Ethypharm
- 21.10. Eurofarma
- 21.11. GlaxoSmithKline
- 21.12. Hikma Pharmaceuticals
- 21.13. Johnson & Johnson
- 21.14. Mallinckrodt Pharmaceuticals
- 21.15. Mundipharma
- 21.16. Mylan
- 21.17. Novartis
- 21.18. Pfizer
- 21.19. Purdue Pharma
- 21.20. Sanofi
- 21.21. Stada Arzneimittel
- 21.22. Takeda
- 21.23. Teva Pharmaceuticals
- 22. Assumptions and Acronyms Used
- 23. Research Methodology
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Drug, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Drug, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Drug, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Mode of Sale, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Mode of Sale, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Mode of Sale, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 13: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 14: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 15: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Drug, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Drug, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Drug, 2024 to 2034
Table 25: North America Market Value (US$ Mn) Analysis, by Mode of Sale, 2019 to 2023
Table 26: North America Market Value (US$ Mn) Analysis, by Mode of Sale, 2024 to 2034
Table 27: North America Market Value (US$ Mn) Opportunity Analysis, by Mode of Sale, 2024 to 2034
Table 28: North America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 29: North America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 30: North America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 37: Latin America Market Value (US$ Mn) Analysis, by Drug, 2019 to 2023
Table 38: Latin America Market Value (US$ Mn) Analysis, by Drug, 2024 to 2034
Table 39: Latin America Market Value (US$ Mn) Opportunity Analysis, by Drug, 2024 to 2034
Table 40: Latin America Market Value (US$ Mn) Analysis, by Mode of Sale, 2019 to 2023
Table 41: Latin America Market Value (US$ Mn) Analysis, by Mode of Sale, 2024 to 2034
Table 42: Latin America Market Value (US$ Mn) Opportunity Analysis, by Mode of Sale, 2024 to 2034
Table 43: Latin America Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 44: Latin America Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 45: Latin America Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 49: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 50: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 51: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 52: Western Europe Market Value (US$ Mn) Analysis, by Drug, 2019 to 2023
Table 53: Western Europe Market Value (US$ Mn) Analysis, by Drug, 2024 to 2034
Table 54: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Drug, 2024 to 2034
Table 55: Western Europe Market Value (US$ Mn) Analysis, by Mode of Sale, 2019 to 2023
Table 56: Western Europe Market Value (US$ Mn) Analysis, by Mode of Sale, 2024 to 2034
Table 57: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Mode of Sale, 2024 to 2034
Table 58: Western Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 59: Western Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 60: Western Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 61: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 65: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 66: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 67: Eastern Europe Market Value (US$ Mn) Analysis, by Drug, 2019 to 2023
Table 68: Eastern Europe Market Value (US$ Mn) Analysis, by Drug, 2024 to 2034
Table 69: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Drug, 2024 to 2034
Table 70: Eastern Europe Market Value (US$ Mn) Analysis, by Mode of Sale, 2019 to 2023
Table 71: Eastern Europe Market Value (US$ Mn) Analysis, by Mode of Sale, 2024 to 2034
Table 72: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Mode of Sale, 2024 to 2034
Table 73: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 74: Eastern Europe Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 75: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 76: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 77: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 78: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 79: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 80: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 81: East Asia Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 82: East Asia Market Value (US$ Mn) Analysis, by Drug, 2019 to 2023
Table 83: East Asia Market Value (US$ Mn) Analysis, by Drug, 2024 to 2034
Table 84: East Asia Market Value (US$ Mn) Opportunity Analysis, by Drug, 2024 to 2034
Table 85: East Asia Market Value (US$ Mn) Analysis, by Mode of Sale, 2019 to 2023
Table 86: East Asia Market Value (US$ Mn) Analysis, by Mode of Sale, 2024 to 2034
Table 87: East Asia Market Value (US$ Mn) Opportunity Analysis, by Mode of Sale, 2024 to 2034
Table 88: East Asia Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 89: East Asia Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 90: East Asia Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 91: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 92: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 93: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 94: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 95: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 96: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 97: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug, 2019 to 2023
Table 98: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug, 2024 to 2034
Table 99: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Drug, 2024 to 2034
Table 100: South Asia & Pacific Market Value (US$ Mn) Analysis, by Mode of Sale, 2019 to 2023
Table 101: South Asia & Pacific Market Value (US$ Mn) Analysis, by Mode of Sale, 2024 to 2034
Table 102: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Mode of Sale, 2024 to 2034
Table 103: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 104: South Asia & Pacific Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 105: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
Table 106: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 107: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 108: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 109: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 110: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 111: MEA Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 112: MEA Market Value (US$ Mn) Analysis, by Drug, 2019 to 2023
Table 113: MEA Market Value (US$ Mn) Analysis, by Drug, 2024 to 2034
Table 114: MEA Market Value (US$ Mn) Opportunity Analysis, by Drug, 2024 to 2034
Table 115: MEA Market Value (US$ Mn) Analysis, by Mode of Sale, 2019 to 2023
Table 116: MEA Market Value (US$ Mn) Analysis, by Mode of Sale, 2024 to 2034
Table 117: MEA Market Value (US$ Mn) Opportunity Analysis, by Mode of Sale, 2024 to 2034
Table 118: MEA Market Value (US$ Mn) Analysis, by End User, 2019 to 2023
Table 119: MEA Market Value (US$ Mn) Analysis, by End User, 2024 to 2034
Table 120: MEA Market Value (US$ Mn) Opportunity Analysis, by End User, 2024 to 2034
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Drug, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Drug, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Drug, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Mode of Sale, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Mode of Sale, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Mode of Sale, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by End User, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by End User, 2024 to 2034
Figure 17: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 18: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 19: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 20: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 21: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 22: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 23: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 24: North America Market Share Analysis by Country, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Drug, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Drug, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Drug, 2024 to 2034
Figure 33: North America Market Share and BPS Analysis by Mode of Sale, 2024 & 2034
Figure 34: North America Market Y-o-Y Growth Projections by Mode of Sale, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis by Mode of Sale, 2024 to 2034
Figure 36: North America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 37: North America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 38: North America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 39: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 40: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 41: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 42: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 43: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 49: Latin America Market Share and BPS Analysis by Drug, 2024 & 2034
Figure 50: Latin America Market Y-o-Y Growth Projections by Drug, 2024 to 2034
Figure 51: Latin America Market Attractiveness Analysis by Drug, 2024 to 2034
Figure 52: Latin America Market Share and BPS Analysis by Mode of Sale, 2024 & 2034
Figure 53: Latin America Market Y-o-Y Growth Projections by Mode of Sale, 2024 to 2034
Figure 54: Latin America Market Attractiveness Analysis by Mode of Sale, 2024 to 2034
Figure 55: Latin America Market Share and BPS Analysis by End User, 2024 & 2034
Figure 56: Latin America Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 57: Latin America Market Attractiveness Analysis by End User, 2024 to 2034
Figure 58: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 59: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 60: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 61: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 62: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 65: Western Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 66: Western Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 67: Western Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 68: Western Europe Market Share and BPS Analysis by Drug, 2024 & 2034
Figure 69: Western Europe Market Y-o-Y Growth Projections by Drug, 2024 to 2034
Figure 70: Western Europe Market Attractiveness Analysis by Drug, 2024 to 2034
Figure 71: Western Europe Market Share and BPS Analysis by Mode of Sale, 2024 & 2034
Figure 72: Western Europe Market Y-o-Y Growth Projections by Mode of Sale, 2024 to 2034
Figure 73: Western Europe Market Attractiveness Analysis by Mode of Sale, 2024 to 2034
Figure 74: Western Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 75: Western Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 76: Western Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 77: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 78: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 79: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 80: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 81: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 82: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 83: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 84: Eastern Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 85: Eastern Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 86: Eastern Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 87: Eastern Europe Market Share and BPS Analysis by Drug, 2024 & 2034
Figure 88: Eastern Europe Market Y-o-Y Growth Projections by Drug, 2024 to 2034
Figure 89: Eastern Europe Market Attractiveness Analysis by Drug, 2024 to 2034
Figure 90: Eastern Europe Market Share and BPS Analysis by Mode of Sale, 2024 & 2034
Figure 91: Eastern Europe Market Y-o-Y Growth Projections by Mode of Sale, 2024 to 2034
Figure 92: Eastern Europe Market Attractiveness Analysis by Mode of Sale, 2024 to 2034
Figure 93: Eastern Europe Market Share and BPS Analysis by End User, 2024 & 2034
Figure 94: Eastern Europe Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 95: Eastern Europe Market Attractiveness Analysis by End User, 2024 to 2034
Figure 96: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 97: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 98: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 99: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 100: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 101: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 102: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 103: East Asia Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 104: East Asia Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 105: East Asia Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 106: East Asia Market Share and BPS Analysis by Drug, 2024 & 2034
Figure 107: East Asia Market Y-o-Y Growth Projections by Drug, 2024 to 2034
Figure 108: East Asia Market Attractiveness Analysis by Drug, 2024 to 2034
Figure 109: East Asia Market Share and BPS Analysis by Mode of Sale, 2024 & 2034
Figure 110: East Asia Market Y-o-Y Growth Projections by Mode of Sale, 2024 to 2034
Figure 111: East Asia Market Attractiveness Analysis by Mode of Sale, 2024 to 2034
Figure 112: East Asia Market Share and BPS Analysis by End User, 2024 & 2034
Figure 113: East Asia Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 114: East Asia Market Attractiveness Analysis by End User, 2024 to 2034
Figure 115: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 116: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 117: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 118: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 119: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 120: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 121: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 122: South Asia & Pacific Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 123: South Asia & Pacific Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 124: South Asia & Pacific Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 125: South Asia & Pacific Market Share and BPS Analysis by Drug, 2024 & 2034
Figure 126: South Asia & Pacific Market Y-o-Y Growth Projections by Drug, 2024 to 2034
Figure 127: South Asia & Pacific Market Attractiveness Analysis by Drug, 2024 to 2034
Figure 128: South Asia & Pacific Market Share and BPS Analysis by Mode of Sale, 2024 & 2034
Figure 129: South Asia & Pacific Market Y-o-Y Growth Projections by Mode of Sale, 2024 to 2034
Figure 130: South Asia & Pacific Market Attractiveness Analysis by Mode of Sale, 2024 to 2034
Figure 131: South Asia & Pacific Market Share and BPS Analysis by End User, 2024 & 2034
Figure 132: South Asia & Pacific Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 133: South Asia & Pacific Market Attractiveness Analysis by End User, 2024 to 2034
Figure 134: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 135: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 136: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 137: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 138: MEA Market Share Analysis by Country, 2024 & 2034
Figure 139: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 140: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 141: MEA Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 142: MEA Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 143: MEA Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 144: MEA Market Share and BPS Analysis by Drug, 2024 & 2034
Figure 145: MEA Market Y-o-Y Growth Projections by Drug, 2024 to 2034
Figure 146: MEA Market Attractiveness Analysis by Drug, 2024 to 2034
Figure 147: MEA Market Share and BPS Analysis by Mode of Sale, 2024 & 2034
Figure 148: MEA Market Y-o-Y Growth Projections by Mode of Sale, 2024 to 2034
Figure 149: MEA Market Attractiveness Analysis by Mode of Sale, 2024 to 2034
Figure 150: MEA Market Share and BPS Analysis by End User, 2024 & 2034
Figure 151: MEA Market Y-o-Y Growth Projections by End User, 2024 to 2034
Figure 152: MEA Market Attractiveness Analysis by End User, 2024 to 2034
- FAQs -
How big is the opioid overdose treatment market in 2024?
The global opioid overdose treatment market has been valued at US$ 1.54 billion in 2024.
What is the demand outlook for opioid overdose treatment solutions by 2034?
Worldwide sales of opioid overdose treatment solutions are evaluated to reach US$ 3.1 billion by 2034.
What is the forecasted growth rate of the global market?
The global market is projected to expand at 7.2% CAGR from 2024 to 2034.
What is the contribution of North America to global market revenue share?
North America is approximated to account for 43.9% of the global market share by 2034.
At what rate is the market evaluated to expand in South Korea?
Demand for opioid overdose treatment solutions in South Korea is analyzed to increase at 7.8% CAGR through 2034.
How much share of the global market are opioid antagonists forecasted to hold?
Opioid antagonists are forecasted to account for 34.3% share of the global market by 2034.
Who are the leading players in the opioid overdose treatment market?
Some of the leading market players are AstraZeneca, Bayer, Collegium Pharmaceutical, EMS Pharma, and GlaxoSmithKline.
Related Reports
Opioid Overdose Treatment Market